Vir Biotechnology has embarked on a pivot toward oncology and infectious disease therapeutics following commercial and clinical challenges. The company recently initiated a Phase I trial for VIR-5525, a dual-masked T-cell engager designed with PRO-XTEN technology for selective tumor activation, evaluated as monotherapy and with Keytruda in solid tumors expressing EGFR. This shift is supported by a licensing pact with Sanofi, including milestone payments and royalties. Vir aims to leverage its platform for safer, targeted immunotherapies.